SEARCH

SEARCH BY CITATION

References

  • 1
    Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol ther 2002; 16: 1895902.
  • 2
    Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997; 32: 124755.
  • 3
    Croucher PI, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporos Int 1993; 3: 23641.
  • 4
    Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002; 8: 8792.
  • 5
    Van staa T, Cooper C, Samuels Brusse L, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2004; 125: 15917.
  • 6
    Stepan JJ. Prediction of bone loss in postmenopausal women. Osteoporos Int 2000; 11(Suppl. 6): S4554.
  • 7
    Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 2000; 11(Suppl. 6): 5565.
  • 8
    Clowes JA, Eastell R. The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14: 21332.
  • 9
    Robinson RJ, Iqbal SJ, Abrams K, al Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol ther 1998; 12: 699705.
  • 10
    Schoon EJ, Geerling BG, Van Dooren IM, et al. Abnormal bone turnover in long-standing Crohn's disease in remission. Aliment Pharmacol ther 2001; 15: 78392.
  • 11
    Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107: 10319.
  • 12
    Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 43944.
  • 13
    Barland P, Lipstein E. Selection and use of laboratory tests in the rheumatic diseases. Am J Med 1996; 100: 16S23S.
  • 14
    Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 7480.
  • 15
    Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997; 181: 25766.
  • 16
    De Vos M, De Keyser F, Mielants H, Cuvelier C, Veys E. Review article: bone and joint diseases in inflammatory bowel disease. Aliment Pharmacol ther 1998; 12: 397404.
  • 17
    Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001; 44: 100312.
  • 18
    Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000; 119: 12038.
  • 19
    Leiper K, Woolner J, Mullan MM, et al. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease. Gut 2001; 49: 7904.
  • 20
    Shaheen SO, Sterne JA, Thompson RL, Songhurst CE, Margetts BM, Burney PG. Dietary antioxidants and asthma in adults: population-based case-control study. Am J Respir Crit Care Med 2001; 164: 18238.
  • 21
    Trebble T, Arden NK, Stroud MA, et al. Inhibition of tumour necrosis factor-α and interleukin-6 production by mononuclear cells following dietary fish oil supplementation in healthy men and response to antioxidant co-supplementation. Br J Nutr 2003; 90: 40512.
  • 22
    Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 699704.
    Direct Link:
  • 23
    Brignola C, Campieri M, Bazzocchi G, Farruggia P, Tragnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986; 91: 14904.
  • 24
    Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996; 334: 155760.
  • 25
    Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999; 353: 45961.
  • 26
    Mazlam MZ, Hodgson HJ. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992; 33: 7738.
  • 27
    Brignola C, Lanfranchi GA, Campieri M, et al. Importance of laboratory parameters in the evaluation of Crohn's disease activity. J Clin Gastroenterol 1986; 8: 2458.
  • 28
    Wigmore SJ, Fearon KC, Maingay JP, Garden OJ, Ross JA. Effect of interleukin-2 on peripheral blood mononuclear cell cytokine production and the hepatic acute phase protein response. Clin Immunol 2002; 104: 17482.
  • 29
    Wigmore SJ, Maingay JP, Fearon KC, O'Riordain MG, Ross JA. Effect of interleukin-4 on pro-inflammatory cytokine production and the acute phase response in healthy individuals and in patients with cancer or multiple organ failure. Clin Sci (Lond) 1998; 95: 34754.
  • 30
    Miyamoto T, Ohneda O, Arai F, et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001; 98: 254454.
  • 31
    Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 30511.
  • 32
    Roux S, Orcel P. Bone loss. Factors that regulate osteoclast differentiation: an update. Arthritis Res 2000; 2: 4516.
  • 33
    MacDonald BR, Gowen M. Cytokines and bone. Br J Rheumatol 1992; 31: 14955.
  • 34
    Pietschmann P, Grisar J, Thien R, et al. Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractures. Exp Gerontol 2001; 36: 174959.
  • 35
    Barrett KE. Cytokines: sources, receptors and signalling. Baillieres Clin Gastroenterol 1996; 10: 115.
  • 36
    Phipps RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. Immunol Today 1991; 12: 34952.
  • 37
    Yaqoob P, Newsholme EA, Calder PC. Comparison of cytokine production in cultures of whole human blood and purified mononuclear cells. Cytokine 1999; 11: 6005.
  • 38
    Takayanagi H, Kim S, Taniguchi T. Signalling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res 2002; 4(Suppl. 3): S22732.
  • 39
    Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999; 265: 14450.
  • 40
    Arron JR, Choi Y. Bone versus immune system. Nature 2000; 408: 5356.
  • 41
    Sasaki T, Hiwatashi N, Yamazaki H, Noguchi M, Toyota T. The role of interferon gamma in the pathogenesis of Crohn's disease. Gastroenterol Jpn 1992; 27: 2936.